- Home
- NUVB vs BCAT Comparison
NUVB vs BCAT Comparison
Compare NUVB & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUVB | BCAT |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NUVB | BCAT |
|---|---|---|
| Price | $4.30 | $13.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 5.1M | 640.7K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.38% |
| EPS Growth | ★ 71.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,902,000.00 | N/A |
| Revenue This Year | $209.36 | N/A |
| Revenue Next Year | $41.60 | N/A |
| P/E Ratio | ★ N/A | $11.22 |
| Revenue Growth | ★ 698.96 | N/A |
| 52 Week Low | $4.05 | $12.92 |
| 52 Week High | $9.75 | $16.20 |
Technical Indicators
Market Signals| Indicator | NUVB | BCAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 52.06 |
| Support Level | $4.17 | $13.43 |
| Resistance Level | $5.11 | $16.10 |
| Average True Range (ATR) | 0.24 | 0.27 |
| MACD | 0.07 | 0.10 |
| Stochastic Oscillator | 70.55 | 81.82 |
Price Performance
Historical ComparisonAbout NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.